Investment
Features
FeesSafety
Academy
More
Pluang+

Compare IDEXX Laboratories, Inc. (IDXX) vs Schlumberger NV (SLB) Price & Performance

IDEXX Laboratories, Inc.Trade
Schlumberger NVTrade

Price performance (Past 24H)

Key statistics

IDEXX Laboratories, Inc. vs Schlumberger NV — how do they compare? IDEXX Laboratories, Inc. trades at $569.65 (market cap $46.22B), while Schlumberger NV trades at $52.67 (market cap $79.67B). The key difference: Schlumberger NV is the larger of the two by market cap, and Schlumberger NV pays a 2.2% dividend while IDEXX Laboratories, Inc. pays none. Which is the better fit depends on your goals.

IDXXSLB
Market Cap
$46.22B$79.67B
Sector
HealthEnergy
52-Week High
$766.68$58.01
52-Week Low
$526.44$31.72
Enterprise Value
$47.12B$88.40B
Dividend Yield
2.2%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

IDEXX Laboratories, Inc.

IDEXX Laboratories (IDXX) trades at $570.58, down 4.23% over 24 hours, with a bullish technical signal and strong fundamentals. The stock has consistently beaten earnings estimates, with Q2 2026 EPS of $4.27 surpassing the $3.94 expectation. Revenue growth remains robust, supported by a 74.21% ROE and expanding diagnostic offerings. Recent news highlights product expansion, including a dual-species cardiac test, reinforcing its market leadership in veterinary diagnostics.

The outlook is positive, driven by durable competitive advantages and international growth potential. However, elevated valuation multiples and competitive pressures pose risks. Analyst consensus is bullish with a $683.33 price target, suggesting significant upside from current levels, though investors should monitor execution on guidance and macroeconomic headwinds.

Schlumberger NV

SLB (NYSE: SLB) trades at $53.02, down 0.34% on the day, with strong technical momentum as moving averages signal bullish sentiment. The company reported three consecutive quarterly earnings beats, with Q2 2026 EPS of $0.55 exceeding expectations. Revenue trends show stability at $35.7B in 2025, though net income margin declined to 8.53%. Analyst consensus remains overwhelmingly positive with 85% buy ratings and a $63 price target representing 19% upside potential.

SLB's outlook is supported by robust digital and production systems growth, though Middle East exposure and net debt pose near-term risks. The stock offers 2.25% dividend yield with recent quarterly payouts of $0.30. While technical indicators show some overbought conditions with RSI at 74, fundamental strength and Wall Street optimism suggest continued upside potential, balanced by geopolitical and margin compression risks.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About IDEXX Laboratories, Inc.

Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.

Read more on IDXX

About Schlumberger NV

Schlumberger is the largest oilfield service firm in the world, with expertise in myriad disciplines, including reservoir performance, well construction, production enhancement, and more recently, digital solutions. It maintains a reputation as one of the industry's leading innovators, which has earned it dominant share in numerous end markets.

Read more on SLB